Format

Send to

Choose Destination
BMC Pediatr. 2019 Jun 27;19(1):210. doi: 10.1186/s12887-019-1566-8.

Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III).

Collaborators (125)

Franz AR, Rüdiger M, Poets CF, Benders M, van Bel F, Allegaert K, Naulaers G, Bassler D, Klebermaß-Schrehof K, Vento M, Guimarães H, Stiris T, Cattarossi L, Metsäranta M, Vanhatalo S, Mazela J, Metsvaht T, van Veldhuizen C, Engel C, Maiwald CA, von Oldershausen G, Bergmann I, Weiss M, Wichera CJBR, Eichhorn A, Raubuch M, Schuler B, van Veldhuizen CKW, Laméris B, Jacobs Y, van der Vlught-Meijer R, Griesmaier E, Brandner J, Tackoen M, Reibel R, Lecart C, Cornette L, Malfilatre G, Viellevoye R, Metsvaht T, Ilmoja ML, Saik P, Käär R, Andresson P, Metsaranta M, Franz AR, Schloesser R, Ott T, Winkler S, Hoehn T, Teig N, Schroth M, Thome UH, Ehrhardt H, Cattarossi L, Mauro I, Baraldi E, Carnielli V, Paterlini G, Napolitano M, Faldini PF, Lista G, Visintin G, Barbarini M, Pagani L, Mastretta E, Vento G, Fumagalli M, Binotti M, van Weissenbruch MM, van Straaten HLM, Benders MJNL, Annink KV, van Bel F, Dudink J, Derks JB, de Boer IP, Meijssen CB, de Haan TR, van Rooij LG, van Hillegersberg JL, van Dongen M, Bruinenberg J, Dijkman KP, van Houten MA, van der Schoor SRD, Stiris T, Salvesen B, Schneider M, Nestaas E, Nakstad B, Mazela J, Karpinski L, Gulczynska E, Królak-Olejnik B, Bokiniec R, Vilan AI, de Pinho LF, Ferraz C, Pereira A, Barroso R, da Graça AM, Tomé T, Pinto F, Vento M, Rodilla JM, Lubián S, Camprubí MC, Suazo JAH, Valverde E, Lorenzo JRF, Orgado JM, Boix H, Parrilla FJ, Moral-Pumarega MT, Maletzki J, Knoepfli C, Hagmann C, Schulzke S, Stocker M, Birkenmaier A, Riedel T, Ehni HJ, Janvier A, Marckmann G.

Author information

1
University Hospital Tuebingen, Calwerstr. 7, 72076, Tuebingen, Germany.
2
Center for Pediatric Clinical Studies (CPCS), University Hospital Tuebingen, Tuebingen, Germany.
3
Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands.
4
Universitätsklinikum C. G. Carus - Medizinische Fakultät der TU Dresden, Dresden, Germany.
5
University Hospitals Leuven, Leuven, Belgium.
6
UniversitaetsSpital Zuerich, Zuerich, Switzerland.
7
Medizinische Universitaet Wien, Wien, Austria.
8
Hospital Universitario y Politécnico La Fe, Valencia, Spain.
9
Centro Hospitalar Universitário São João Porto, Porto, Portugal.
10
Oslo Universitetssykehus HF, Oslo, Norway.
11
Azienda sanitaria universitaria integrata di Udine, Udine, Italy.
12
Helsinki University Hospital (HUS), Helsinki, Finland.
13
Poznan University of Medical Sciences - Department of Neonatology, Poznan, Poland.
14
Tartu University Hospital, Tartu, Estonia.
15
ACE Pharmaceuticals BV, Zeewolde, The Netherlands.
16
University Hospital Tuebingen, Calwerstr. 7, 72076, Tuebingen, Germany. Axel.Franz@med.uni-tuebingen.de.
17
Center for Pediatric Clinical Studies (CPCS), University Hospital Tuebingen, Tuebingen, Germany. Axel.Franz@med.uni-tuebingen.de.

Abstract

BACKGROUND:

Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia.

METHODS:

This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24 months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age ≥ 36 weeks and a birth weight ≥ 2500 g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion.

DISCUSSION:

This trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia.

TRIAL REGISTRATION:

NCT03162653, www.ClinicalTrials.gov , May 22, 2017.

KEYWORDS:

Allopurinol; Brain injury; Cerebral palsy; Childbirth outcome; Hypothermia therapy; Hypoxic-ischemic encephalopathy; Neonatal oxygen deficiency; Perinatal asphyxia

PMID:
31248390
DOI:
10.1186/s12887-019-1566-8
Free full text

Supplemental Content

Full text links

Icon for BioMed Central
Loading ...
Support Center